Bright Minds Biosciences Inc. (DRUG) Stock Overview
Explore Bright Minds Biosciences Inc.’s financial performance, market position, analyst ratings, and future outlook.
Bright Minds Biosciences Inc. (DRUG)
Key Financials
Key Financials
Market Cap
757.7M
P/E Ratio
-39.23
EPS (TTM)
$-2.08
ROE
-0.13%
DRUG Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Bright Minds Biosciences Inc. (NASDAQ: DRUG) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Bright Minds Biosciences Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DRUG on the NASDAQ shows an RSI of 51.88, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $108.68 for the NASDAQ listing.
Key metrics behind Bright Minds Biosciences Inc.'s NASDAQ-traded stock include a P/E ratio of -39.23 and a market capitalization of 757.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of DRUG on the NASDAQ.